INNOVIVA, INC. Treasury Stock, Value, Acquired, Cost Method
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- INNOVIVA, INC. treasury stock, value, acquired, cost method for the quarter ending 2024-06-30 was $5.26M, a 43.36% decline year-over-year.
- INNOVIVA, INC. treasury stock, value, acquired, cost method for the quarter ending 2024-03-31 was $9.66M, a 76.27% decline year-over-year.
- INNOVIVA, INC. treasury stock, value, acquired, cost method for the quarter ending 2023-09-30 was $11.07M.
- INNOVIVA, INC. treasury stock, value, acquired, cost method for the quarter ending 2023-06-30 was $9.29M.
- INNOVIVA, INC. treasury stock, value, acquired, cost method for fiscal 2023 was $76.48M, a 799.49% increase from fiscal 2022.
- INNOVIVA, INC. treasury stock, value, acquired, cost method for fiscal 2022 was $8.50M, a 97.84% decline from fiscal 2021.
- INNOVIVA, INC. treasury stock, value, acquired, cost method for fiscal 2021 was $394.15M.
| Period end | Treasury Stock, Value, Acquired, Cost Method 3 month | Treasury Stock, Value, Acquired, Cost Method 12 month |
|---|---|---|
| 2024-06-30 | $5.26M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $9.66M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $76.48M 10-K/A · filed 2024-03-05 | |
| 2023-09-30 | $11.07M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $9.29M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $40.73M 10-Q · filed 2024-11-06 | |
| 2022-12-31 | $8.50M 10-K · filed 2025-02-26 | |
| 2021-12-31 | $394.15M 10-K/A · filed 2024-03-05 | |
| 2021-06-30 | $394.15M 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |